narcolepsy with cataplexy: Narcolepsy with cataplexy is a sleep disorder characterized by excessive day-time sleepiness associated with uncontrollable sleep urges and cataplexy (loss of muscle tone often triggered by pleasant emotions).
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
292 |
4. Check minimum number of eventsNone |
292 |
5. Include endpointsNone |
292 |
6. Filter based on genotype QC (FinnGen only) |
264 |
Control definitions (FinnGen only)
- Control exclude
- G6_EPIPAROX
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G47
- Name in latin
- Narcolepsia
Similar endpoints
↥List of similar endpoints to
Narcolepsy and cataplexy
based on the number of shared cases.
Similar with more cases:
- Sleep disorders (combined)
- Autoimmune diseases
- Episodal and paroxysmal disorders
- Used for control exclusion in common control thyroid runs
- Neurological diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1805 | 929 | 870 |
| Only index persons | 1664 | 880 | 784 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 32.44 | 28.45 | 36.61 |
| Only index persons | 30.04 | 27.56 | 32.81 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 264 | 154 | 110 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 35.98 | 32.13 | 41.37 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 274
- Matched controls
- 2740
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G47.4
ICD-10 Finland
Narcolepsy and cataplexy
+∞
307.7
249
*
G47.3
ICD-10 Finland
Sleep apnoea
38.5
175.6
122
56
N06BA07
ATC
modafinil; oral
+∞
131.0
115
*
214
Kela drug reimbursment
Severe and chronic narcolepsy
+∞
108.8
97
*
TAB00
NOMESCO Finland
Lumbar puncture
23.3
98.3
78
46
N06BA04
ATC
methylphenidate; oral
15.0
89.7
94
92
282
Kela drug reimbursment
Sodium oxybat
+∞
89.6
81
*
N07XX04
ATC
sodium oxybate; oral
+∞
63.0
58
*
G47.9
ICD-10 Finland
Sleep disorder, unspecified
20.4
60.6
49
29
R5140
NOMESCO Finland
Monitoring the use of the aid
16.1
50.6
46
34
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
8.8
38.8
54
74
G47.1
ICD-10 Finland
Disorders of excessive somnolence [hypersomnias]
+∞
38.4
36
*
N06AX16
ATC
venlafaxine; oral
6.0
38.1
84
187
3035, ,
Kela drug reimbursment
+∞
33.0
31
*
N04BD01
ATC
selegiline; oral
58.0
26.8
31
6
R06.5
ICD-10 Finland
Mouth breathing
7.0
24.4
40
65
N07XX11
ATC
pitolisant; oral
+∞
24.3
23
*
N06AA04
ATC
clomipramine; systemic
37.2
23.9
30
9
3471A
ICD-9 Finland
Cataplexy and narcolepsy[NARCOLEPSIA]
+∞
23.3
22
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
7.4
23.2
36
55
N04BC05
ATC
pramipexole; oral
7.0
22.5
37
60
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.6
22.0
46
95
N06BA14
ATC
solriamfetol; oral
+∞
21.1
20
*
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
6.0
18.6
35
65
R53
ICD-10 Finland
Malaise and fatigue
3.3
18.6
98
397
N06AX18
ATC
reboxetine; oral
29.7
16.8
22
8
N06AB04
ATC
citalopram; systemic
3.5
15.8
66
229
34700
ICD-8 Finland
Other disease of brain, Cataplexy and narcolepsy
+∞
15.8
15
*
R03CA02
ATC
ephedrine; oral
+∞
15.8
15
*
R40.0
ICD-10 Finland
Somnolence
47.9
15.3
18
*
WX780
NOMESCO Finland
Remote monitoring CPAP
+∞
13.7
13
*
3472A
ICD-9 Finland
Cataplexy and narcolepsy[OBSTRUKTIIVINEN UNIAPNEA]
+∞
12.6
12
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
12.6
72
298
A02BA02
ATC
ranitidine; systemic
3.4
12.2
50
170
G44.2
ICD-10 Finland
Tension-type headache
4.0
12.1
37
103
WX722
NOMESCO Finland
PEEP
20.0
11.7
17
9
WX723
NOMESCO Finland
CPAP therapy
+∞
11.5
11
*
Z2445
NOMESCO Finland
Psychologist
4.7
11.3
27
62
XA800
NOMESCO Finland
Neuropsychological investigation
5.4
11.2
23
46
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
5.3
10.7
22
44
P06
ICPC
Sleep disturbance
3.2
10.7
48
172
E66.01
ICD-10 Finland
Obesity due to excess calories
3.5
10.7
40
128
J45.9
ICD-10 Finland
Asthma, unspecified
2.8
10.5
62
259
XA420
NOMESCO Finland
Extensive sleep examination
114.2
10.5
11
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
16.9
10.5
16
10
E66.8
ICD-10 Finland
Other obesity
5.0
10.4
23
49
N06AX12
ATC
bupropion; oral
3.6
10.4
37
114
N03AX12
ATC
[U] gabapentin; oral
3.2
10.4
46
163
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.0
10.1
49
183
N03AX16
ATC
[U] pregabalin
2.8
10.1
60
251
A04
ICPC
Weakness/tiredness general
2.7
10.0
61
259
E66.00
ICD-10 Finland
Metabolic syndrome
5.2
10.0
21
43
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
27.2
9.9
13
5
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
9.8
76
363
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
2.8
9.7
58
243
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
9.6
9.7
19
21
R03BB04
ATC
tiotropium bromide; inhalant
4.2
9.7
27
70
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
+∞
9.4
9
*
A02BC03
ATC
lansoprazole; oral
2.5
9.4
69
320
R03AC02
ATC
salbutamol; inhalant
2.2
9.3
164
1101
UJF32
NOMESCO Finland
Coloscopy
2.5
9.1
65
298
N06AA09
ATC
amitriptyline; systemic
4.3
9.0
24
60
H02AB06
ATC
prednisolone; systemic
2.2
9.0
126
770
G45.9
ICD-10 Finland
Transient cerebral ischaemic attack, unspecified
25.0
9.0
12
5
N03AE01
ATC
clonazepam; systemic
4.9
9.0
20
43
R07.4
ICD-10 Finland
Chest pain, unspecified
2.4
9.0
73
355
S97
ICPC
Chronic ulcer skin
4.5
8.8
22
52
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.5
8.5
30
92
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.6
8.5
29
87
F32.9
ICD-10 Finland
Depressive episode, unspecified
2.8
8.5
47
189
R51.80
ICD-10 Finland
Headache
2.6
8.4
55
241
G47.2
ICD-10 Finland
Disorders of the sleep-wake schedule
+∞
8.4
8
*
G43.1
ICD-10 Finland
Migraine with aura [classical migraine]
4.7
8.0
19
43
U04
ICPC
Incontinence urine
4.7
8.0
19
43
R42
ICD-10 Finland
Dizziness and giddiness
2.5
8.0
55
246
XG466
NOMESCO Finland
Sleep oxymetry
12.3
7.7
13
11
N06AB03
ATC
fluoxetine; oral
2.9
7.6
37
138
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.6
7.6
26
78
N03AX09
ATC
lamotrigine; oral
4.1
7.6
21
54
T90
ICPC
Diabetes non-insulin dependent
2.5
7.6
56
259
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
7.6
111
680
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.0
7.5
35
128
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
4.1
7.1
20
52
L03
ICPC
Low back symptom/complaint
2.1
7.0
85
483
R55
ICD-10 Finland
Syncope and collapse
3.1
6.9
31
110
N03AG01
ATC
valproic acid; systemic, rectal
4.3
6.9
18
44
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.9
6.8
33
123
M79.6
ICD-10 Finland
Pain in limb
2.0
6.8
115
736
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.5
6.6
44
193
L17
ICPC
Foot/toe symptom/complaint
2.0
6.6
86
500
R03DC03
ATC
montelukast; oral
2.4
6.6
52
247
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.3
6.5
55
269
J45
ICD-10 Finland
Asthma
2.9
6.5
32
120
M54.4
ICD-10 Finland
Lumbago with sciatica
2.4
6.5
50
235
H02AB04
ATC
methylprednisolone; systemic
2.6
6.5
39
163
A10BA02
ATC
metformin; oral
2.2
6.5
65
342
G40.9
ICD-10 Finland
Epilepsy, unspecified
71.4
6.5
7
*
N02AX02
ATC
tramadol; systemic, rectal
2.0
6.4
97
594
B01AB05
ATC
enoxaparin; parenteral
2.1
6.4
71
388
103
Kela drug reimbursment
Diabetes, insulin-treated
2.2
6.4
60
307
215
Kela drug reimbursment
Diabetes, non-insulin-treated
2.3
6.4
56
279
N03AF02
ATC
oxcarbazepine; oral
18.5
6.3
9
5
J45.1
ICD-10 Finland
Nonallergic asthma
3.0
6.2
28
100
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.0
6.2
13
17
SPAT1262
SPAT
Handing over of treatment supplies
2.5
6.2
41
180
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.8
6.1
31
118
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
12.9
6.1
10
8
AA1AD
NOMESCO Finland
CT of head and brain
2.2
6.1
55
277
R06AE07
ATC
cetirizine; oral
1.9
6.0
126
855
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.9
6.0
18
49
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.2
6.0
55
278
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
47
32
17.52
54.09
1.1
1.5
2.26
11.30
e6/l
0.56
35
27
142
919
2.13
8.64
5.5
6.3
1.21
1.21
mmol/l
0.06
119
801
16
17
9.92
8.40
1.1
1.1
—
—
—
0
0
129
816
2.10
8.22
5.2
5.5
1.21
1.21
mmol/l
0.05
117
763
58
264
2.52
8.15
1.8
1.6
1323.59
1143.41
nmol/l
0.78
45
211
126
792
2.09
8.15
5.2
4.5
36.97
36.75
g/l
0.19
121
757
27
87
3.33
7.08
4.0
3.9
1.73
2.38
mmol/l
0.49
22
61
14
17
8.61
6.91
1.1
1.2
—
—
—
0
0
43
190
2.50
6.37
9.6
5.0
—
—
—
0
0
14
21
6.96
6.12
1.1
1.1
—
—
—
0
0
144
1022
1.86
5.97
6.1
6.3
9.23
11.14
umol/l
3.44
139
974
159
1166
1.87
5.92
5.0
4.3
6.77
6.48
mmol/l
1.02
149
1075
77
450
1.99
5.73
1.9
1.6
1.19
1.43
mg/l
0.35
54
336
122
836
1.83
5.55
2.5
1.8
106.64
96.78
pmol/l
1.41
67
432
168
1271
1.83
5.49
9.7
9.4
3.99
4.07
e9/l
0.17
151
1102
13
21
6.44
5.45
1.2
1.1
—
—
—
0
0
84
522
1.88
5.15
5.3
4.0
5.31
8.67
mg/mmol
0.90
52
331
196
1573
1.86
5.09
8.6
7.4
76.47
79.03
u/l
0.35
190
1490
76
461
1.90
5.00
4.0
2.9
1055.24
1197.81
ng/l
0.10
69
387
98
654
1.78
4.70
5.0
3.2
20.70
46.13
ng/l
2.27
59
392
7
6
11.92
4.30
1.4
1.0
—
—
—
0
0
29
129
2.40
4.23
1.8
1.5
—
—
—
0
0
192
1574
1.73
4.17
4.8
3.8
10.64
9.81
mm/h
0.39
177
1477
90
611
1.70
3.95
3.2
2.5
52.44
70.13
u/l
1.04
84
574
234
2047
1.98
3.95
5.2
4.0
5.95
5.68
mmol/l
2.12
218
1902
41
220
2.02
3.80
1.5
1.6
—
—
—
0
0
61
374
1.81
3.80
1.6
1.7
471.28
54925796.64
pmol/l
0.76
50
335
149
1161
1.62
3.77
4.2
2.9
80.38
93.90
ug/l
0.74
142
1109
49
282
1.90
3.72
1.6
1.7
—
—
—
0
0
93
648
1.66
3.66
3.0
3.0
2.33
2.36
mmol/l
1.88
86
601
89
614
1.67
3.64
4.7
3.2
0.00
0.00
estimate
-0.00
29
219
80
539
1.68
3.57
1.7
1.6
20.32
19.86
nmol/l
0.10
71
463
81
551
1.67
3.48
2.7
2.0
2.66
2.61
mg/l
0.12
68
478
36
191
2.02
3.45
3.4
7.9
0.76
0.70
mmol/l
0.04
26
161
147
1161
1.57
3.38
4.8
3.2
0.00
0.00
estimate
-0.00
30
233
48
287
1.82
3.23
3.4
2.3
2.47
2.36
g/l
0.67
43
267
87
623
1.58
2.98
1.4
1.4
1.00
1.97
u/ml
0.70
23
170
145
1167
1.52
2.90
4.9
3.3
0.00
0.00
estimate
-0.00
30
216
88
636
1.57
2.89
1.7
1.6
—
—
—
0
0
142
1144
1.50
2.79
5.0
3.2
0.00
0.00
estimate
-0.00
29
234
5
6
8.46
2.76
1.0
1.3
—
—
—
0
0
14
54
2.68
2.75
2.4
2.2
—
—
—
0
0
12
44
2.81
2.58
1.3
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
7
7.25
2.56
1.4
1.3
—
—
—
0
0
28
152
1.94
2.54
1.3
1.4
—
—
—
0
0
36
213
1.79
2.51
1.5
1.6
—
—
—
0
0
76
547
1.54
2.50
4.4
3.0
1.02
1.02
kg/l
0.18
58
355
231
2092
1.66
2.44
16.5
11.2
89.83
90.18
ml/min/173m2
0.08
216
1881
121
964
1.46
2.41
2.8
2.4
74.43
73.60
nmol/l
0.12
112
891
5
8
6.34
2.38
1.4
1.0
—
—
—
0
0
11
39
2.90
2.37
1.3
1.4
342.00
341.57
ug/g
—
6
23
6
14
4.36
2.16
1.3
3.6
13.67
12.00
%
—
6
14
63
453
1.51
2.06
4.0
2.6
332.76
335.34
umol/l
0.07
55
415
42
275
1.62
2.05
2.5
1.9
—
—
—
0
0
8
26
3.14
2.03
1.5
2.8
22.44
25.18
nmol/l
—
8
26
196
1740
1.44
2.00
5.0
4.1
14.36
14.62
pmol/l
0.96
186
1603
50
348
1.53
1.90
1.5
1.3
22.91
11.94
u/ml
0.30
20
143
21
115
1.89
1.89
4.0
7.5
24.44
24.96
mmol/l
0.43
21
115
11
46
2.45
1.87
1.3
1.3
—
—
—
0
0
47
324
1.54
1.86
2.8
2.0
—
—
—
0
0
49
342
1.53
1.84
2.5
2.7
2.41
2.44
mmol/l
1.00
42
310
226
2076
1.51
1.81
6.2
4.8
1.60
1.82
mu/l
4.03
213
1943
29
180
1.68
1.75
1.8
2.4
5927.94
7219.85
u/l
—
8
80
5
13
3.90
1.72
1.4
1.1
—
—
—
0
0
47
332
1.50
1.67
5.3
3.1
91.45
571.20
ng/l
0.88
29
229
27
168
1.67
1.62
3.9
3.0
1.88
2.01
mmol/l
0.07
21
134
5
14
3.62
1.62
1.4
3.6
—
—
—
0
0
243
2285
1.56
1.54
19.0
11.5
19.94
23.45
mg/l
1.20
215
1777
7
27
2.63
1.52
4.0
3.3
16.99
15.15
%
—
7
27
6
22
2.76
1.44
1.0
1.2
—
—
—
0
0
214
1977
1.38
1.38
7.5
4.9
39.56
37.71
mmol/mol
1.95
202
1883
33
228
1.51
1.32
3.8
2.5
5.31
8.86
umol/l
1.29
27
202
26
172
1.57
1.26
4.0
3.1
6.09
5.74
kpa
0.90
21
166
105
889
1.29
1.25
4.8
3.1
0.11
0.01
estimate
0.43
27
196
7
143
0.48
1.24
1.4
1.6
87.17
61.25
ug/l
—
7
124
11
56
2.00
1.24
1.1
1.2
—
—
—
0
0
177
1608
1.28
1.18
3.8
2.8
45.84
39.88
u/l
0.58
168
1539
5
20
2.53
1.15
1.2
1.1
—
—
—
0
0
21
135
1.60
1.15
4.9
3.5
80.93
70.79
ng/l
0.25
15
121
119
1034
1.27
1.13
3.6
2.6
—
—
estimate
—
0
0
32
228
1.46
1.12
6.2
3.5
34.15
32.15
%
0.39
20
153
27
188
1.48
1.06
1.2
1.3
51.30
183.22
u/ml
—
10
73
11
60
1.87
1.04
1.2
1.3
—
2.78
—
0
11
48
374
1.34
1.02
1.5
1.3
9.60
26.11
iu/ml
2.75
19
117
5
23
2.19
0.98
1.4
1.3
—
—
—
0
0
6
27
2.25
0.94
1.2
1.1
—
—
—
0
0
62
508
1.28
0.93
2.4
2.2
—
—
—
0
0
7
130
0.53
0.90
1.4
1.5
—
—
—
0
0
16
103
1.59
0.89
1.4
1.3
—
—
—
0
0
14
87
1.64
0.89
1.3
1.6
—
—
—
0
0
10
56
1.82
0.89
1.9
1.9
0.32
2.10
ug/l
—
10
51
189
1760
1.24
0.87
3.1
3.7
—
—
—
0
0
18
259
0.67
0.85
1.6
1.6
1182.39
982.41
mu/l
0.26
18
227
11
65
1.72
0.83
1.1
1.3
—
—
—
0
0
8
46
1.76
0.83
3.0
2.5
134.50
127.87
g/l
—
8
39
65
549
1.24
0.76
2.6
2.3
—
—
—
0
0
9
54
1.69
0.75
2.1
1.6
—
—
—
0
0
65
551
1.24
0.74
4.5
2.9
0.21
0.37
e6/l
1.13
51
386
7
39
1.82
0.73
1.9
1.5
—
—
—
0
0
15
101
1.51
0.72
3.6
2.7
119.53
170.67
ng/l
0.37
15
90
62
525
1.23
0.71
2.5
2.2
—
—
—
0
0
5
26
1.94
0.71
1.2
1.3
—
—
—
0
0
5
26
1.94
0.71
1.2
1.3
—
—
—
0
0
5
26
1.94
0.71
1.2
1.3
—
—
—
0
0
5
26
1.94
0.71
2.0
1.3
—
—
—
0
0
9
58
1.57
0.70
1.1
1.8
—
—
—
0
0
9
58
1.57
0.70
1.6
1.5
—
—
—
0
0
28
214
1.34
0.70
5.7
3.9
213.21
231.30
u/l
0.95
28
208
10
61
1.66
0.69
1.2
1.9
—
—
—
0
0
7
42
1.68
0.69
1.3
1.9
—
—
—
0
0
53
444
1.24
0.67
1.5
1.5
—
—
—
0
0
13
86
1.54
0.67
1.2
1.3
—
—
—
0
0
10
63
1.61
0.62
1.4
1.3
—
—
—
0
0
26
330
0.77
0.60
1.3
1.8
3.59
3.38
ratio
0.40
20
254
6
37
1.64
0.56
1.0
1.3
—
—
—
0
0
9
60
1.52
0.55
1.6
1.3
—
—
—
0
0
76
675
1.17
0.54
3.9
2.8
0.04
0.01
estimate
0.40
26
191
6
40
1.51
0.52
1.8
1.4
—
—
—
0
0
19
146
1.32
0.48
2.5
2.2
0.59
0.22
e6/l
0.46
19
136
19
241
0.77
0.46
1.4
1.7
3.54
3.44
mmol/l
0.14
14
166
7
51
1.38
0.44
1.0
1.3
—
80.20
—
0
5
24
194
1.26
0.43
2.0
2.4
31.67
31.27
u/l
0.03
18
169
8
58
1.39
0.42
2.1
1.9
253.88
233.53
pmol/l
—
8
53
5
33
1.52
0.41
2.0
1.4
—
—
—
0
0
0
16
0.00
0.41
0.0
3.1
—
81.42
—
0
16
0
17
0.00
0.41
0.0
2.1
—
—
—
0
0
5
35
1.44
0.39
1.2
1.3
—
—
—
0
0
5
36
1.40
0.38
9.0
3.0
19.88
7.19
pmol/l
—
5
36
17
135
1.28
0.36
2.1
2.7
61.00
74.97
ml/min/173m2
—
8
61
15
117
1.30
0.36
1.9
1.7
—
—
—
0
0
14
109
1.30
0.34
4.4
10.4
94.68
94.75
%
0.05
14
109
6
46
1.31
0.33
1.2
1.2
—
—
—
0
0
6
46
1.31
0.33
1.3
1.2
—
—
—
0
0
12
154
0.77
0.33
1.2
1.0
—
—
—
0
0
209
2033
1.12
0.30
4.7
3.4
1.33
1.21
mmol/l
1.17
189
1904
7
55
1.28
0.30
1.4
1.2
—
—
—
0
0
8
64
1.26
0.27
1.6
1.3
—
—
—
0
0
9
72
1.26
0.26
2.2
2.0
3.98
3.49
g/l
—
9
67
223
2184
1.11
0.25
5.4
4.1
4.50
4.64
mmol/l
1.28
209
2061
15
179
0.83
0.24
1.4
1.3
—
—
—
0
0
92
872
1.08
0.22
1.8
1.8
1.45
1.33
mmol/l
0.61
80
772
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
—
—
0
0
36
327
1.12
0.20
4.5
2.6
0.36
1.17
e6/l
2.94
19
164
6
48
1.26
0.20
1.0
1.2
—
—
—
0
0
6
50
1.20
0.20
1.8
1.4
—
—
—
0
0
221
2177
1.08
0.16
5.2
3.9
1.40
1.46
mmol/l
1.43
203
2041
9
81
1.11
0.15
1.7
1.5
—
—
—
0
0
12
103
1.17
0.14
1.3
1.5
52.20
52.94
ug/l
0.03
12
103
17
190
0.89
0.13
4.2
2.6
—
—
—
0
0
33
307
1.09
0.12
5.1
2.8
0.83
3.14
e6/l
2.88
16
145
10
86
1.17
0.11
1.9
1.6
—
0.00
—
0
17
41
388
1.07
0.10
4.7
4.6
20.40
23.32
%
0.60
17
184
5
63
0.79
0.08
1.2
1.3
2.98
3.28
ug/l
—
5
58
5
63
0.79
0.08
3.2
1.7
—
—
—
0
0
14
127
1.11
0.08
1.6
2.1
—
—
—
0
0
8
76
1.05
0.07
1.1
1.1
—
—
—
0
0
8
77
1.04
0.07
1.1
1.1
—
—
—
0
0
9
101
0.89
0.06
1.2
1.4
—
—
—
0
0
10
90
1.12
0.05
1.1
1.5
—
—
—
0
0
13
136
0.95
0.00
1.4
1.3
151.14
265.11
miu/ml
—
8
75
221
2208
1.00
0.00
5.6
4.4
2.68
2.76
mmol/l
0.60
206
2078
13
129
1.01
0.00
1.4
1.7
—
—
—
0
0
29
295
0.98
0.00
3.8
3.2
0.52
0.83
ug/l
2.19
16
179
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
9.27
—
0
5
Mortality – FinRegistry
↥Association
Association between endpoint G6_NARCOCATA and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_NARCOCATA | 1.095 [0.82, 1.46] | 0.53 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 635 males with G6_NARCOCATA died.
Mortality risk
Mortality risk for people of age
years, who have G6_NARCOCATA.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.215% |
| 5 | No data | 1.126% |
| 10 | No data | 2.798% |
| 15 | No data | 5.169% |
| 20 | No data | 9.036% |
Relationships between endpoints
↥Index endpoint: G6_NARCOCATA – Narcolepsy and cataplexy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data